Thyrocare Technologies has announced a final dividend of Rs. 7.00 per equity share for FY 2025-26, bringing the total annual dividend to Rs. 9.33 per share post-bonus. The company also unveiled key leadership changes, including the re-appointment of Mr. Rahul Franklin Guha as MD & CEO, and approved an investment of Rs. 5.50 crore into its subsidiary, Think Health Diagnostics. Additionally, the company is broadening its memorandum of association to support future growth.
Financial Performance and Dividend Payout
Following the conclusion of the financial year ended March 31, 2026, the Board has recommended a final dividend of Rs. 7.00 per equity share. This is subject to approval at the upcoming Annual General Meeting. When combined with the interim dividend already paid, the total payout for the financial year reaches Rs. 9.33 per equity share (post-bonus adjustment).
Strategic Leadership Updates
The company announced significant board-level transitions. Mr. Rahul Franklin Guha has been re-appointed as Chairman, Managing Director, and Chief Executive Officer for a five-year term, effective May 4, 2027. Concurrently, the Board welcomed Mr. Uday Patel Kadam and Mr. Gaurav Verma as Additional Directors. These changes coincide with the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah, both of whom stepped down from their non-executive director roles effective May 7, 2026.
Investment in Think Health Diagnostics
To support its long-term growth strategy, the Board has approved a capital infusion of up to Rs. 5.50 crore into its wholly-owned subsidiary, Think Health Diagnostics Private Limited. This funding will be utilized to support business operations, capital expenditure, and working capital requirements as the subsidiary focuses on expanding its affordable, high-volume diagnostics platform.
Governance and Operational Expansion
In addition to leadership and financial updates, the company is updating its Memorandum of Association to align with the Companies Act, 2013. The scope of the business is being broadened to include a wider range of healthcare activities, such as clinical laboratories, radiology, and the development of data-driven digital platforms. Furthermore, the company has appointed M/s. Price Waterhouse Chartered Accountants LLP as its new Statutory Auditors for a five-year term starting from the 26th Annual General Meeting.
Source: BSE
